A group of Venrock Healthcare Capital Partners entities and two individual principals filed a Schedule 13G with the SEC on October 30, 2026, disclosing beneficial ownership of 6,850,237 shares of Lycia Therapeutics, Inc. common stock as of October 23, 2026.

Key Highlights

  • Aggregate beneficial ownership: The nine reporting persons collectively reported shared beneficial ownership of 6,850,237 shares of Lycia Therapeutics common stock, representing 11.9% of the class.
  • No sole voting or dispositive power: Each reporting person disclosed 0.00 shares of sole voting power and 0.00 shares of sole dispositive power; all 6,850,237 shares are held under shared voting and shared dispositive power.
  • Component holdings disclosed: The filing identifies 1,769,496 shares held by VHCP III and 177,092 shares held by VHCP Co-Investment III, with 4,251,859 shares attributed to an additional entity (Venrock Healthcare Capital Partners EG, L.P.) before the filing text was truncated.
  • Reporting persons: The group includes Venrock Healthcare Capital Partners III, L.P.; VHCP Co-Investment Holdings III, LLC; Venrock Healthcare Capital Partners EG, L.P.; VHCP Management III, LLC; VHCP Management EG, LLC; Venrock Healthcare Capital Partners XP, L.P.; VHCP Management XP, LLC; Nimish Shah; and Bong Y. Koh.
  • Triggering event date: The event requiring the filing occurred on October 23, 2026, according to the statement.
  • Security class: The shares reported are common stock with a par value of $0.0001 per share, CUSIP 55081P100.

Venrock Healthcare Group Reports Group Ownership of Lycia Therapeutics Shares

According to the Schedule 13G filed with the SEC, nine reporting persons acting as a group disclosed a combined beneficial ownership position of 6,850,237 shares of Lycia Therapeutics, Inc. (NASDAQ:LYCA) common stock. The filing states that the triggering event occurred on October 23, 2026. Each of the nine reporting persons listed the same aggregate figure of 6,850,237 shares, representing 11.9% of the outstanding class, with all voting and dispositive power held on a shared basis and none held solely.

The reporting persons include three Delaware-organized limited partnerships, four Delaware-organized limited liability companies, and two individual United States citizens, Nimish Shah and Bong Y. Koh. According to the filing, Shah and Koh, along with the affiliated management entities, are identified as part of the group for purposes of the Schedule 13G. The filing lists principal offices in New York, New York and Palo Alto, California.

The filing provides a partial breakdown of how the aggregate shares are held across the group. Specifically, the filing states that 1,769,496 shares are held by Venrock Healthcare Capital Partners III, L.P.; 177,092 shares are held by VHCP Co-Investment Holdings III, LLC; and 4,251,859 shares are attributed to Venrock Healthcare Capital Partners EG, L.P. The filing text as provided ends before a complete allocation across all entities is stated. Lycia Therapeutics, Inc. is headquartered at 400 East Jamie Court, Suite 200, South San Francisco, CA 94080, according to the filing.

What Was Disclosed

A nine-member group led by Venrock Healthcare Capital Partners entities and including individuals Nimish Shah and Bong Y. Koh filed a Schedule 13G reporting shared beneficial ownership of 6,850,237 shares, or 11.9%, of Lycia Therapeutics, Inc. common stock as of October 23, 2026.